uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
uniQure N.V. (Nasdaq: QURE) said it closed an upsized underwritten public offering of 5,686,813 ordinary shares at $45.50 each, including 741,758 shares from full exercise of the underwriters’ option. Gross proceeds were about $259 million before underwriting fees and expenses. Net proceeds will fund AMT-130 commercialization readiness, a confirmatory study, other clinical programs, business development, and general corporate purposes.
How this was made
The 30-second read
Why it matters
The offering provides capital earmarked for commercialization readiness and AMT-130 commercialization launches plus a confirmatory study, which can reduce financing uncertainty but increases share count.
Market read
A ~$259M gross equity raise at $45.50/share is a concrete, tradable catalyst affecting dilution expectations and funding runway for AMT-130 commercialization.
What to watch
Net proceeds (after underwriting discounts/expenses) and any concurrent guidance/operational updates are not provided here; those could materially change the dilution vs de-risking balance.
Background
uniQure announced and then closed an underwritten public offering, including full exercise of an option to purchase additional shares.
Ticker impact
uniQure closed an upsized public offering of 5,686,813 shares at $45.50, raising ~$259M gross, with proceeds for AMT-130 commercialization and studies.
Near-term trading likely weighs dilution over improved funding runway; direction depends on whether investors view proceeds as de-risking commercialization execution.
This is a primary capital-raise disclosure with specific size/price and stated use of proceeds; it typically supports liquidity while pressuring per-share metrics via dilution.
Market effects
Gene-therapy peers may see read-across on how companies are funding commercialization readiness via equity.
Limited direct regional impact; primarily US-listed biotech sentiment.
Low global relevance beyond biotech financing conditions.
Counterpoint
If investors believe AMT-130 commercialization execution is the key bottleneck, the raise could be viewed as removing a major funding constraint, outweighing dilution.
Key entities
- issueruniQure N.V.
Nasdaq-listed gene therapy company that closed the upsized public offering.
- product_candidateAMT-130
Lead gene therapy program referenced as a use of proceeds for commercialization and confirmatory study.
- transaction_partiesUnderwriters (Leerink Partners, Stifel, Guggenheim Securities, RBC Capital Markets)
Joint bookrunning managers for the offering; option to purchase additional shares was fully exercised.
